🔎 Trials Near Me

Utama › Kanser Hati (Karsinoma Hepatoselular) › Illinois › Chicago

Kajian klinikal Kanser Hati (Karsinoma Hepatoselular) di Chicago, IL

16 kajian untuk Kanser Hati (Karsinoma Hepatoselular) sedang mencari peserta di lokasi dalam dan sekitar Chicago (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Mengambil pesertaFasa 1
  • Exelixis Clinical Site #26, Chicago
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT05176483

National Liver Cancer Screening Trial

Mengambil pesertaFasa 4
  • Northwestern University, Chicago
Umur 18 hingga 85 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06084234

Defining the Ablative Dose for Y-90 TARE

Mengambil pesertaFasa 2
  • Northwestern University, Chicago
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT07586046

Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)

Mengambil pesertaKajian pemerhatian
  • RUSH University Medical Center, Chicago
  • University of Chicago, Chicago
Umur 22 ke atas · Semua jantina · Dikemas kini 11 Sep 2026 · NCT06486454

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Mengambil pesertaFasa 3
  • Research Site, Chicago
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06921785

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Mengambil pesertaFasa 1/2
  • Lurie Children's Hospital-Chicago, Chicago
12 Months – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04851119

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Mengambil pesertaFasa 3
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT07166406

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Mengambil pesertaFasa 2
  • University of Chicago Comprehensive Cancer Center, Chicago
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT05168163

Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer

Mengambil pesertaFasa 1/2
  • Northwestern University, Chicago
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Jun 2026 · NCT07042919

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Mengambil pesertaFasa 1
  • Clinical Trial Site, Chicago
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Jun 2026 · NCT06600321

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

Mengambil pesertaFasa 2
  • Northwestern University, Chicago
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Mei 2026 · NCT05620771

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Mengambil pesertaFasa 4
  • University of Chicago Medical Center, Chicago
Umur 18 hingga 64 · Semua jantina · Dikemas kini 22 Jan 2026 · NCT04373564

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Mengambil pesertaKajian pemerhatian
  • Massive Bio SYNERGY-AI site, Chicago
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774

The Dragon PLC Trial (DRAGON-PLC)

Mengambil peserta
  • Rush University Medical Center, Chicago
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Mei 2025 · NCT06914648

Kajian Kanser Hati (Karsinoma Hepatoselular) di bandar lain

Kajian lain di Chicago

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.